- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr. Ravi Vij Discusses Benefits/Efficacy of Carfilzomib and Revlimid
Dr. Ravi Vij, Associate Professor of Medicine, Washington University School of Medicine, St. Louis, MO, serves in the Section of Stem Cell Transplant and Leukemia, Division of Oncology. In this interview, he discusses several new molecules headed for FDA approval to treat multiple myeloma.
In addition, Dr. Vij talks about the efficacy of carfilzomib and lenalidomide (Brand name: Revlimid), two drugs seeking accelerated approval by the FDA. He also discusses new molecules in Phase III clinical trials. "This is an exciting time. Outcomes have continued to improve over the past decade for patients with multiple myeloma. However, we have a way to go, as multiple myeloma is still fatal in most patients," said Dr. Vij.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
